| Literature DB >> 27680663 |
Hayley V MacDonald1, Blair T Johnson2, Tania B Huedo-Medina3, Jill Livingston4, Kym C Forsyth5, William J Kraemer6, Paulo T V Farinatti7, Linda S Pescatello8.
Abstract
BACKGROUND: Aerobic exercise (AE) is recommended as first-line antihypertensive lifestyle therapy based on strong evidence showing that it lowers blood pressure (BP) 5 to 7 mm Hg among adults with hypertension. Because of weaker evidence showing that dynamic resistance training (RT) reduces BP 2 to 3 mm Hg among adults with hypertension, it is recommended as adjuvant lifestyle therapy to AE training. Yet, existing evidence suggests that dynamic RT can lower BP as much or more than AE. METHODS ANDEntities:
Keywords: exercise training; high blood pressure; hypertension; lifestyle; meta‐analysis; systematic review
Mesh:
Substances:
Year: 2016 PMID: 27680663 PMCID: PMC5121472 DOI: 10.1161/JAHA.116.003231
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Flow chart detailing the systematic search of potential reports (n) and selection process of included dynamic resistance training studies. AET indicates aerobic exercise training; BP, blood pressure; CINAHL, cumulative index to nursing and allied health literature; CET, concurrent exercise training; FITT, Frequency, Intensity, Time and Type; RT, resistance training.
Baseline Sample Characteristics for the Dynamic RT (k=71) and Control (k=63) Intervention Groups
| Characteristic | k | Dynamic RT (n=1305) | k | Control (n=1039) |
|---|---|---|---|---|
| Women, n (%) | 69 | 622 (47.7) | 61 | 477 (45.9) |
| Age, y | 68 | 47.2±19.0 | 61 | 47.2±19.1 |
| Race/ethnicity, n (%) | 71 | 63 | ||
| White | 40 | 775 (59.4) | 36 | 554 (53.3) |
| Asian | 17 | 263 (20.2) | 14 | 227 (21.8) |
| Hispanic/Latino/Caribbean | 13 | 254 (19.5) | 12 | 243 (23.4) |
| Black/African American | 1 | 13 (1.0) | 1 | 15 (1.4) |
| Sedentary, n (%) | 53 | 926 (71.0) | 47 | 764 (73.5) |
| BP medication, n (% using) | 49 | 177 (13.6) | 42 | 172 (16.5) |
| BP classification, n (%) | ||||
| Normal | 16 | 242 (18.5) | 12 | 164 (15.8) |
| Prehypertension | 41 | 688 (52.7) | 41 | 587 (56.5) |
| Hypertension | 14 | 375 (28.7) | 10 | 292 (28.1) |
| Health status, n (%) | 65 | 54 | ||
| No CVD‐related chronic conditions | 38 | 611 (46.8) | 33 | 446 (42.9) |
| CVD‐related chronic conditions | 27 | 499 (38.2) | 21 | 380 (36.6) |
| 1 chronic disease/health condition | 16 | 280 (21.5) | 11 | 158 (15.2) |
| 2 to 3 chronic diseases/health conditions | 7 | 69 (5.3) | 6 | 68 (6.5) |
| ≥4 chronic diseases/health conditions | 4 | 150 (11.5) | 4 | 154 (14.8) |
| Chronic conditions reported per sample | 1.9±1.3 | 2.0±1.3 | ||
| Body composition | ||||
| Body weight, kg | 61 | 75.0±11.7 | 59 | 74.1±12.0 |
| BMI, kg/m2 | 60 | 26.8±3.4 | 58 | 26.6±3.7 |
| Waist circumference, cm | 17 | 96.9±9.3 | 17 | 96.1±10.0 |
| Body fat (%) | 36 | 29.7±6.9 | 36 | 29.3±7.9 |
| Fat mass, kg | 11 | 26.4±6.8 | 11 | 26.7±7.2 |
| Lean mass, kg | 20 | 50.9±11.2 | 20 | 49.4±11.1 |
| Resting hemodynamics | ||||
| Systolic BP, mm Hg | 71 | 126.7±10.3 | 70 | 126.3±9.4 |
| Diastolic BP, mm Hg | 71 | 76.8±8.7 | 70 | 76.5±8.6 |
| Mean arterial pressure, mm Hg | 71 | 93.2±8.0 | 70 | 93.2±8.2 |
| Pulse pressure, mm Hg | 71 | 49.4±8.3 | 70 | 49.8±6.8 |
| Heart rate, beats/min | 41 | 70.1±6.9 | 40 | 69.1±7.3 |
| Strength and fitness measures | ||||
| Upper body strength, kg | 18 | 44.5±31.3 | 10 | 43.4±36.5 |
| Lower body strength, kg | 24 | 92.3±58.8 | 16 | 97.3±69.7 |
| Cardiorespiratory fitness, mL/kg per minutes | 24 | 28.6±9.9 | 23 | 29.7±9.4 |
Statistics are summarized as mean±SD, or the number of participants and proportion of the total RT and control samples, n (%). BMI indicates body mass index; BP, blood pressure; CVD, cardiovascular disease; k, number of observations; RT, resistance training.
Participation in <30 minutes of moderate intensity, physical activity on ≤2 days/week;130 in the absence of physical activity data, samples that were reported as “sedentary” were also included.
BP classification published in the Seventh Report of the Joint National Committee.131
Samples were free from CVD‐related chronic diseases or health conditions.
Studies that reported CVD‐related chronic diseases or health conditions among subjects (or medications used to treat diseases/conditions) were categorized based on the total number reported in their sample (ie, 1, 2 to 3, or ≥4; ranging from 1 to 5).31, 46
Chronic diseases/health conditions130 were not mutually exclusive (ie, subjects could have 1 or more); health conditions included hypertension, metabolic syndrome (MetS), and obesity, dyslipidemia (ie, CVD risk factors); chronic diseases: type 2 diabetes mellitus (T2DM), chronic heart failure, and nonalcoholic fatty liver disease (ie, CVD or metabolic diseases).
The most commonly reported combinations included: hypertension, MetS, or dyslipidemia with T2DM (see Table S5 for individual study details).
Upper/lower body strength was reported for 25 of 33 RT and 14 of 24 control groups, respectively; only those reported in kilograms (kg) are summarized.
Baseline fitness was reported for 37 RT and 36 control groups; only relative oxygen uptake assessed by peak or maximal tests are summarized.
Summary of Dynamic RT Intervention Characteristics (k=71)
| Program Characteristics | k | Mean±SD | Range | Median |
|---|---|---|---|---|
| Participants (n) at baseline | 71 | 21.1±14.9 | 8.0, 72.0 | 15.0 |
| Participants (n) post‐RT | 71 | 18.4±11.4 | 8.0, 60.0 | 14.0 |
| Attrition in RT group (%) | 71 | 8.5±13.1 | 0.0, 53.0 | 0.0 |
| Exercise adherence (%) | 46 | 92.3±8.9 | 60.0, 100.0 | 95.0 |
| Dynamic RT FITT | ||||
| Length (weeks) | 71 | 14.4±7.9 | 6.0, 48.0 | 12.0 |
| Frequency (days/week) | 71 | 2.8±0.6 | 2.0, 5.0 | 3.0 |
| Intensity or Load | ||||
| % of 1‐RM | 38 | 64.7±13.0 | 30.0, 87.5 | 65.0 |
| % of MVC | 2 | 90.0±14.4 | 80.0, 100.0 | |
| 10 to 15 RM | 8 | 12.6% | ||
| 8 to 12 RM | 8 | 12.5% | ||
| 6 to 16 RM | 2 | 3.1% | ||
| OMNI‐RT Scale | 2 | 3.1% | ||
| Theraband (not specified) | 3 | 4.7% | ||
| % of 1‐RM (estimated) | 63 | 67.2±12.4 | 30.0, 100.0 | 70.0 |
| MET (estimated) | 71 | 4.7±1.8 | 2.8, 8.5 | 3.8 |
| Time (total work/session) | ||||
| Number of exercises/session | 69 | 7.9±2.9 | 1.0, 16.0 | 7.0 |
| Number sets/exercise | 67 | 2.8±0.9 | 1.0, 5.0 | 3.0 |
| Number repetitions/set | 65 | 11.0±3.8 | 5.0, 30.0 | 10.0 |
| Rest interval/recovery (s) | 30 | 96.3±43.3 | 15.0, 180.0 | 90.0 |
| Type of RT protocol | ||||
| Conventional RT | 54 | 76.0% | ||
| Circuit‐style RT | 10 | 14.3% | ||
| Theraband | 4 | 5.7% | ||
| Ankle or shin weights | 2 | 2.9% | ||
| Muscle groups targeted | ||||
| Upper and lower body | 63 | 91.3% | ||
| Lower body | 4 | 5.8% | ||
| Unilateral, upper body | 2 | 2.9% | ||
% indicates percentage; FITT, frequency, intensity, time, and type; k, number of observations; MET, metabolic equivalent unit; MVC, maximum voluntary contraction; Range, minimum, maximum values; Reps, repetitions; RM, repetition maximum; RT, resistance training; s, seconds.
% of 1‐RM was estimated for studies that reported RT intensity/load as 1‐RM range or MVC (%); represents the mean 1‐RM (%) after combining the estimated and reported values (k=38).
Standardized estimate of RT intensity/load; METs were assigned to all RT interventions so that RT intensity/loads could be quantified across studies, including unreported data (k=12) and units other than 1‐RM or MVC (k=39).
Multiple Moderator Model: SBP Response to Dynamic RT (k=69)a
| Moderator Dimension/Level |
| β |
| SBP ∆ (mm Hg) | |
|---|---|---|---|---|---|
| Resting SBP of RT sample, mm Hg | −0.311 | 0.011 | |||
| Normal=115±11 (k | 0.00 (−0.23, 0.23) | 0.0 (−2.5, 2.5) | |||
| Prehypertension=130±13 (k | −0.23 (−0.39, −0.07) | −3.0 (−5.1, −1.0) | |||
| Hypertension=142±14 (k | −0.41 (−0.64, −0.19) | −5.7 (−9.0, −2.7) | |||
| Race/ethnicity of RT sample | 0.354 | 0.002 | |||
| White samples (k | −0.00 (−0.20, 0.20) | 0.0 (−2.6, 2.6) | |||
| Nonwhite samples (k | −0.36 (−0.56, −0.16) | −4.7 (−7.3, −2.1) | |||
| BP medication use of RT sample | 0.261 | 0.034 | |||
| Taking BP medication (k | −0.03 (−0.29, 0.23) | −0.4 (−3.8, 3.0) | |||
| Not taking BP medication (k | −0.33 (−0.48, −0.17) | −4.3 (−6.2, −2.2) | |||
| RT exercises performed/session | −0.221 | 0.043 | |||
| <8 RT exercises=6 (k | −0.11 (−0.29, 0.08) | −1.4 (−4.4, 1.0) | |||
| ≥8 RT exercises=12 (k | −0.34 (−0.55, −0.12) | −4.4 (−7.2, −1.6) | |||
| Primary study outcome | −0.238 | 0.032 | |||
| BP focused outcome (k | −0.30 (−0.49, −0.10) | −3.9 (−6.4, −1.3) | |||
| Non‐BP focused outcome (k | −0.06 (−0.26, 0.14) | −0.8 (−3.4, 1.8) | |||
| Additive SBP model | Non‐white samples | −1.02 (−1.36, −0.67) | −14.3 (−19.0, −9.4) | ||
| White samples | −0.66 (−0.97, −0.35) | −9.2 (−13.6, −4.9) | |||
Resting SBP is presented as mean±SD. ∆ indicates change; BP, blood pressure; k, number of observations; RT, resistance training; SBP, systolic BP; β, standardized coefficient represents unique variance explained by moderator.
Multiple R 2 (variance explained by model, adjusted for number of moderators)=67.1%; I2 residual (variance unexplained by model)=27.3%.
Predicted weighted mean effect size (d+); estimate of the magnitude of SBP reduction among the RT group relative to control, while statistically controlling for the presence of each moderator shown in the above model (held constant at their mean), except for moderator/level of interest. This model also controls for (not shown): 1 versus 2 RT groups (β=−0.235; P=0.050) and SBP×RT exercises interaction (β=0.174; P=0.133).
SBP ∆= (95% CIs) back‐converted to mm Hg. For each moderator/level of interest, (95% CIs) were transformed arithmetically using the SD corresponding to the sample mean (130±13 mm Hg): ∆= (95% CI)×13 mm Hg, with the exception of normal SBP: ∆= (95% CI)×11 mm Hg; hypertension SBP and additive SBP model: ∆= (95% CI)×14 mm Hg.
(P<0.05): normal SBP; white samples; taking medication; 6 exercises; non‐BP outcome.
Normal and prehypertension SBP.
Indicates the moderator dimensions/levels that conferred the largest SBP reductions and were used to generate the additive SBP model.
Multiple Moderator Model: DBP Response to Dynamic RT (k=71)a
| Moderator Dimension/Level |
| β |
| DBP ∆ (mm Hg) | |
|---|---|---|---|---|---|
| Resting DBP of RT sample, mm Hg | −0.317 | 0.023 | |||
| Normal=69±7 (k | −0.13 (−0.30, 0.31) | −0.9 (−2.1, 2.2) | |||
| Prehypertension=83±9 (k | −0.37 (−0.59, −0.15) | −3.3 (−5.3, −1.4) | |||
| Hypertension=92±10 (k | −0.52 (−0.84, −0.19) | −5.2 (−8.4, −1.9) | |||
| BP medication use of RT sample | 0.260 | 0.028 | |||
| Currently taking BP medication (k | −0.13 (−0.38, 0.11) | −1.2 (−3.4, 1.0) | |||
| Not taking BP medication (k | −0.39 (−0.55, −0.23) | −3.5 (−5.0, −2.1) | |||
| Frequency of RT sessions | −0.262 | 0.020 | |||
| <3 days=2 days weekly (k | −0.10 (−0.31, 0.11) | −0.9 (−2.8, 1.0) | |||
| ≥3 days=4 days weekly (k | −0.50 (−0.76, −0.23) | −4.5 (−6.8, −2.1) | |||
| Methodological study quality | 0.296 | 0.019 | |||
| Lower quality=49% satisfied (k | −0.41 (−0.62, −0.19) | −3.7 (−5.6, −1.7) | |||
| Moderate quality=63% satisfied (k | −0.20 (−0.38, −0.03) | −1.8 (−3.4, −0.3) | |||
| Higher quality=82% satisfied (k | −0.03 (−0.28, 0.22) | −0.3 (−2.5, 2.0) | |||
| Additive DBP model | Non‐white samples | −1.03 (−1.45, −0.62) | −10.3 (−14.5, −6.2) | ||
| White samples | −0.95 (−1.35, −0.54) | −9.5 (−13.5, −5.2) | |||
Resting DBP is presented as mean±SD. ∆ indicates change; BP, blood pressure; DBP, diastolic blood pressure; k, number of observations; RT, resistance training; β, standardized coefficient represents unique variance explained by moderator.
Multiple R 2 (variance explained by model, adjusted for number of moderators)=49.9%; I2 residual (variance unexplained by model)=19.6%.
Predicted weighted mean effect size (d+); estimate of the magnitude of DBP reduction among the RT group relative to control, while statistically controlling for the presence of each moderator shown in the above model (held constant at their mean), except for the moderator/level of interest. This model also controls for (not shown): race/ethnicity (β=0.097; P=0.382), 1 versus 2 RT groups (β=−0.017; P=0.902), and DBP×RT groups interaction (β=0.248; P=0.056).
DBP ∆= (95% CIs) back‐converted to mm Hg. For each moderator/level of interest, (95% CIs) were transformed arithmetically using the SD corresponding to the sample mean (83±9 mm Hg): ∆= (95% CI)×9 mm Hg, with the exception of normal DBP: ∆= (95% CI)×8 mm Hg; hypertension DBP and additive DBP model: ∆= (95% CI)×10 mm Hg.
(P<0.05): normal DBP; taking medication; 2 days/week; higher quality.
Moderate and higher quality.
Indicates the moderator dimensions/levels that conferred the largest DBP reductions and were used to generate the additive DBP model.